Robin Jones to Survival Rate
This is a "connection" page, showing publications Robin Jones has written about Survival Rate.
Connection Strength
1.578
-
Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy. In Vivo. 2020 Jan-Feb; 34(1):239-245.
Score: 0.159
-
Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy. Med Oncol. 2019 Dec 27; 37(2):13.
Score: 0.158
-
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139.
Score: 0.155
-
Sarcomas and old age: few options for such a large patient population. Future Oncol. 2019 Sep; 15(26s):11-15.
Score: 0.155
-
Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Med Oncol. 2018 Sep 05; 35(11):138.
Score: 0.145
-
Eribulin in advanced liposarcoma and leiomyosarcoma. Expert Rev Anticancer Ther. 2017 08; 17(8):717-723.
Score: 0.133
-
Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug; 35(4):351-7.
Score: 0.095
-
Oncological Outcome After Diagnostic Biopsies in Gastrointestinal Stromal Tumors: A Retrospective Cohort Study. Ann Surg. 2021 12 01; 274(6):e1093-e1098.
Score: 0.045
-
Treatments and Outcomes in Oligometastatic Soft Tissue Soft Sarcoma - A Single Centre Retrospective Analysis. Anticancer Res. 2021 Oct; 41(10):5089-5096.
Score: 0.045
-
Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. Eur J Surg Oncol. 2021 10; 47(10):2595-2601.
Score: 0.044
-
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Med. 2021 04; 10(8):2645-2659.
Score: 0.043
-
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 07; 21(7):923-934.
Score: 0.041
-
Primary iliocaval leiomyosarcomas: The path beyond surgery. Eur J Surg Oncol. 2020 05; 46(5):893-897.
Score: 0.040
-
Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. Ann Surg Oncol. 2019 Dec; 26(13):4699-4706.
Score: 0.039
-
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res. 2019 10 01; 25(19):5808-5817.
Score: 0.038
-
Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clin Cancer Res. 2019 09 01; 25(17):5295-5300.
Score: 0.038
-
Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. AJR Am J Roentgenol. 2018 Jan; 210(1):175-182.
Score: 0.034
-
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 09; 146(3):531-537.
Score: 0.033
-
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 08; 18(8):1089-1103.
Score: 0.033
-
Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study. Anticancer Res. 2015 Nov; 35(11):6213-7.
Score: 0.030
-
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10; 34(8):786-93.
Score: 0.029
-
Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. Acta Oncol. 2012 Apr; 51(4):550-4.
Score: 0.022
-
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol. 2011 Dec; 123(3):553-6.
Score: 0.022